In a phase 2b/3 clinical trial, KSI-301 failed to meet the primary endpoint of noninferior visual acuity gains compared with aflibercept in subjects with wet age-related macular degeneration, according to a Kodiak Sciences press release.
The randomized, double-masked, active comparator-controlled trial enrolled 559 treatment-naive participants in two treatment arms, receiving either KSI-301 5 mg on a flexible long-interval regimen or aflibercept 2 mg on a fixed short-interval regimen. All participants received loading doses at 0, 4 and 8 weeks; those in the aflibercept group received treatment